tirzepatide long covid Weight-Loss Drug Zepbound Is Being Tested as a Treatment for You are invited to join

Key Findings: Most common: Nausea (43%), diarrhea (33%), vomiting (21%) Unique to retatrutide: Dysesthesia (20.9% @ 12mg in TRIUMPH-4, 8.8% @ 9mg) Discontinuation rate: 18.2% in TRIUMPH-4, 11.3% in TRIUMPH-1 (general obesity population) compared to semaglutide 6.9%, tirzepatide 6.2% Good news: Most side effects peak during dose escalation and improve significantly after week 16 Management: Slow titration, dietary modifications, and proper timing dramatically reduce severity Understanding the Three Categories of Side Effects 1

This allows for appropriate dose adjustments if needed

Studies have failed to find evidence that GLP-1 use can cause pancreatic cancer, a possible complication of pancreatitis, so theres still some uncertainty about the exact nature of harm that GLP-1s can cause to the pancreas

Pen or Vial